|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>223</sup>RaCl<sub>2</sub> has also shown promise in other tumour types with bone metastases, including advanced breast cancer and advanced renal cell carcinoma (in combination with anti-vascular endothelial growth factor).
|
31471713 |
2020 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors.
|
31465470 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy.
|
30689402 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC).
|
30158285 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
|
30374686 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sunitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF), is approved for first and second line treatment of advanced renal cell carcinoma (RCC).
|
28676023 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression.
|
29297707 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: Lenvatinib is a new VEGF receptor-targeted tyrosine kinase inhibitor approved in combination with everolimus for second-line therapy in patients with advanced renal cell carcinoma progressing on a first-line VEGF receptor-targeted tyrosine kinase inhibitor.
|
29737893 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.
|
29848570 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the recent approval of the dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, by the U.S. Food and Drug Administration (USFDA), and the European Medicines Agency (EMA), the era of VEGF monotherapy for untreated aRCC appears to be coming to an end for patients with access to the combination therapy.
|
30687324 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesised that axitinib, a more selective VEGF inhibitor than others previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield antitumour activity in patients with treatment-naive advanced renal cell carcinoma.
|
29439857 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma.
|
29530667 |
2018 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma.
|
28810837 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tivozanib (Fotivda<sup>®</sup>) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
28971328 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the efficacy and safety of everolimus as a second-line treatment after the failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy in Japanese patients with advanced renal cell carcinoma.
|
28334974 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we found interleukin-6 as predictive of pazopanib benefit.
|
28683470 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sunitinib, the vascular endothelial growth factor pathway inhibitor, is an established standard-of-care for advanced renal cell carcinoma (RCC).
|
28330808 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In recent years, there has been dramatic expansion of the treatment armamentarium for patients with advanced renal cell carcinoma (aRCC), including drugs targeting vascular endothelial growth factor and mammalian target of rapamycin (mTOR) pathways.
|
28383639 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is also approved in combination with everolimus for the treatment of advanced renal cell carcinoma following ≥1 VEGF-targeted treatment in the US and EU.
|
28236116 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of multiple vascular endothelial growth factor- and mammalian target of rapamycin-targeted therapies in advanced renal cell carcinoma has resulted in significant clinical benefit.
|
27473523 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Axitinib is a selective tyrosine kinase inhibitor of VEGF receptors, approved for advanced renal cell carcinoma (RCC).
|
27586968 |
2016 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced renal cell carcinoma (RCC) remains a largely incurable disease with a grave prognosis despite the availability of a multiplicity of systemic therapies targeted against vascular endothelial growth factor, its receptors, and the mammalian target of rapamycin.
|
25811348 |
2015 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we review novel VEGF-directed agents that are being developed to address the shortcomings of current targeted drugs for the treatment of advanced renal cell carcinoma.
|
23867510 |
2014 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
|
23867511 |
2014 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma.
|
23834452 |
2014 |